Healthcare Industry News: Abbott Vascular
News Release - September 24, 2009
Results from Abbott's PROSPECT Study Provide New Insight into Role of Vulnerable Plaque in Coronary Artery DiseaseSAN FRANCISCO, Sept. 24 (Healthcare Sales & Marketing Network) -- Abbott (NYSE: ABT ) today announced primary results from its groundbreaking PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) clinical trial. PROSPECT is the first prospective natural history study to evaluate the role of vulnerable plaque in unexpected heart attacks and the natural progression of coronary artery disease. Results were presented today during the late-breaking clinical trials session by Gregg W. Stone, M.D., professor of medicine at Columbia University Medical Center, during the 2009 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting.
"We know that certain vulnerable plaques lead to sudden cardiac death, but until now, our understanding of how these plaques progress has been extremely limited," said Dr. Stone, who is also immediate past chairman of the Cardiovascular Research Foundation, New York, and principal investigator of the PROSPECT study. "PROSPECT has provided fundamental insights into our understanding of atherosclerosis. Conventional wisdom has been that if we could identify vulnerable plaques, we would be able to determine who might be at risk for a serious cardiac event and treat them prophylactically."
Vulnerable plaques are inflamed, lipid-rich lesions that form in the walls of the arteries and usually have thin, fibrous caps. The relationship between vulnerable plaque ruptures and sudden cardiac death is well known, but until the PROSPECT study, no systematic effort had been made to prospectively understand the event rate associated with progression of vulnerable plaque. Unlike hardened plaque, vulnerable plaques are often not visible with angiography and do not actually block blood flow in coronary arteries unless their rupture results in a clot.
Among the findings of the 700-patient study, researchers were able to identify the common characteristics of lesions that put patients at highest risk for future cardiac events by using advanced imaging called virtual histology intravascular ultrasound (VH® IVUS) and standard angiography. Going forward, investigators will now have access to more than 40,000 datapoints derived from 150 variables within each of the patients, far beyond the level of assessment of previous interventional studies.
"While the prognosis of patients with acute coronary syndromes undergoing successful stenting and treated with contemporary medical therapy is favorable, we are now able to identify those lesion types with a significantly increased likelihood of causing future cardiovascular events," Stone said.
The PROSPECT study recruited patients who were in need of a PCI (percutaneous coronary intervention) to treat a heart attack or threatened heart attack. Patients consented to collection of additional data as follow-up to their procedure, including VH IVUS imaging and standard angiography. PROSPECT collected data about characteristics of vulnerable plaque lesions that were present but not causing symptoms at the time of the procedure. The goal was to correlate lesion characteristics, patient risk factors and biomarker measurements with subsequent heart attacks and other cardiac events, potentially paving the way for physicians to identify and treat at-risk patients before a heart attack occurs.
In the study, approximately 20 percent of the patient population experienced a major adverse cardiac event (cardiac death, cardiac arrest or heart attack) within three years of enrollment. Half of these events can be attributed to the original "culprit" lesions (those treated with PCI) and half to previously untreated, "non-culprit" lesions of the three-vessel coronary tree. Half of the patients treated for non-culprit events exemplified the classic notion of vulnerable plaque.
The event rate, particularly that attributed to vulnerable plaques specifically, was lower than expected. Further, patients who experienced "non-culprit" events in the years following PCI were more likely to present with progressive or unstable angina, and rarely with cardiac death, arrest or MI. Imaging of the lesions that did progress to events suggests that vulnerable plaque lesions with a large plaque burden and large necrotic core without a visible cap were at especially high risk for future adverse cardiovascular events.
"Abbott's PROSPECT trial is the most comprehensive study ever done on vulnerable plaque and the results shed new light on understanding its role in the progression of coronary artery disease," said John M. Capek, executive vice president, medical devices, Abbott. "As a leader in cardiovascular devices, diagnostics and medicines, Abbott looks forward to sharing these results with the vascular community and adding to our understanding of the disease."
About the PROSPECT Trial
Abbott's PROSPECT trial is the first prospective natural history study to examine the role of vulnerable plaque and how it might progress to a cardiac event. PROSPECT used novel intravascular imaging technology to correlate plaque characteristics, patient risk factors and biomarker measurements with subsequent heart attacks and other cardiac events, potentially paving the way for physicians to identify and treat at-risk patients before a heart attack occurs.
PROSPECT enrolled 700 patients from 40 clinical centers across the United States and Europe. All patients received PCI for acute coronary syndrome (ACS), which included unstable angina, NSTEMI or STEMI. Patient follow up continued for three years. Abbott sponsored the study and VH IVUS imaging technology was provided by Volcano Corporation.
About Abbott Vascular
Abbott Vascular, a division of Abbott, is one of the world's leading vascular care businesses. Abbott Vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by combining the latest medical device innovations with world-class pharmaceuticals, investing in research and development, and advancing medicine through training and education. Headquartered in Northern California, Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products.
Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 72,000 people and markets its products in more than 130 countries.
Abbott's news releases and other information are available on the company's Web site at www.abbott.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsAbbott Receives FDA Emergency Use Authorization for COVID-19 Antibody Blood Test on Alinity(TM) i System
Abbott's TriClip(TM) Becomes First Device of its Kind to Receive CE Mark for Minimally Invasive Tricuspid Valve Repair
Abbott Aims to Optimize TAVI Implants with European Approval of FlexNav(TM) Delivery System for the Company's Portico(TM) Valve